Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.3.9 (glucose-6-phosphatase)
3,081 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Trials were carried out with two groups of birds, White Plymouth times Cornish crosses. A third, control group of birds was also involved in the experiments, reared by the same technology. The only difference consisted in that the air in the premise of the test birds had a lower microbial content which, during the experiments was 2 to 5 times lower than that in the air of the controls. It was found that under the effect of the higher microbial content the blood serum protein drops like the protein content of the liver and heart musculature, the content of free amino acids rises, the amount of triptophane lowers, and the activity of GOT and GPT is enhanced. The birds of the control group show higher enzyme activity so far as the glucose-6-phosphatase of the liver is concerned, lower glycogen content of the liver, and lower blood concentration of glucose. By the end of the trials the broilers of the control group were 50 gr less heavy than the lest birds.
...
PMID:[The effect of microbial contemination of the air on metabolic indices in broiler chickens]. 16 11

The effects of single acute oral doses of 1, 2.1, and 3.5 mg/kg oxamyl (a carbamate insecticide) on selected biochemical parameters in male Sprague-Dawley rats were investigated. The animals exhibited significantly decreased weight gain when compared to control animals. The compound inhibited brain and blood acetylcholinesterase significantly in the first few hours of exposure. Liver glucose-6-phosphatase was inhibited substantially after 7 and 4 days at the levels of 2.1 and 3.5 mg/kg, respectively. Maximum inhibition of liver succinic acid dehydrogenase was noted after 1 day at the level of 1 mg/kg and after 6 hr at the level of 2.1 and 3.5 mg/kg. Significant changes in serum total lipids and glucose were observed when oxamyl was given at 2.1 and 3.5 mg/kg, but serum protein was not affected at any dose level. However, the absence of statistically significant effects between Days 7 and 14 in most of the investigated parameters is indicative of an overall moderate degree of toxicity of oxamyl following acute oral administration of the selected doses.
...
PMID:Acute toxic effects of oxamyl in the rat. 131 38

The effects of high-dose indomethacin (three daily dose, 8.5 mg/kg ip) on pathology and histology, on serum and urine biochemistry, and on various hepatic enzyme activities were studied in rats. Hepatic cytochrome P-450 and aminopyrine N-demethylase were decreased by 52-62%, but glucuronyl transferase fell by only 22%. Hepatic glucose-6-phosphatase, aryl esterase, 6-phosphogluconate dehydrogenase and sulphotransferase remained unchanged, while glucose-6-phosphate dehydrogenase increased by 29%. There were no widespread changes in hepatic and renal pathology or histology, but noteworthy was a mild, focal, centrilobular hepatic response. By contrast, there were severe intestinal lesions: the effects on hepatic enzymes might have been partly a consequence of the intestinal damage. There was a reversible uraemia and significant decreases (20-40% below normal) in both serum albumin and protein, while serum levels of creatinine and aspartate-amino-transferase activity remained constant. A reversible N-acetyl-beta-D-glucoseaminidase (NAG) enzymuria occurred (300% above normal), but no significant proteinuria (less than 300 mg/l). Administration of 16, 16-dimethylprostaglandin F2 alpha(0.5 mg/kg iv) concomitantly with the indomethacin greatly ameliorated the intestinal lesions and prevented the decreases in hepatic drug-metabolizing enzymes. Concomitant 16,16-dimethylprostaglandin F2 alpha did not, however, influence the indomethacin-induced decreases in serum protein, albumin or NAG-enzymuria. It was concluded that indomethacin had a highly selective effect causing a decrease in hepatic cytochrome P-450, which was not accompanied by severe damage to hepatocyte structure.
...
PMID:Comparative effects of indomethacin on hepatic enzymes and histology and on serum indices of liver and kidney function in the rat. 393 37

Serum glucose, serum protein, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and hepatic and renal gluconeogenic enzymes [pyruvate carboxylase (PC), phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-diphosphatase (F-1,6-DPase), and glucose-6-phosphatase (G-6-Pase)] were determined in rats treated daily with cadmium alone (0.25 mg/kg X d, injected ip and in rats pretreated with spironolactone (50 mg/kg x d and 100 mg/kg X d, injected sc) prior to cadmium administration. Rats receiving no treatment, propylene glycol, or spironolactone (100 mg/kg X d, injected sc) were used as controls. The daily treatments were continued for an extended period of 90 d, and the rats were sacrificed at 30-, 60-, and 90-d intervals during the continuous daily treatment schedule. Cadmium treatment significantly increased the amount of serum protein, glucose, serum enzymes, and all the four key gluconeogenic enzymes as compared to controls. Pretreatment of rats with spironolactone 6 h prior to cadmium injection daily antagonized the cadmium effect of the above parameters. It appears from these results that spironolactone reduces the effects of cadmium on the key gluconeogenic enzymes in rat kidney and liver.
...
PMID:Influence of spironolactone on cadmium-induced changes in hepatic and renal gluconeogenic enzymes in rats. 712 May 5

Male Sprague-Dawley rats were administered cadmium chloride 0, 50, 100, 150 and 200 ppm for 30 days. At the end of the treatments, the body weight gains, serum glucose, serum protein, serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were determined. Renal and hepatic key gluconeogenic enzymes; viz., pyruvate carboxylase, phosphoenol pyruvate carboxykinase, fructose-1, 6-diphosphatase and glucose-6-phosphatase were also determined. A significant decrease in body weight gain in rats treated with cadmium was observed. The serum glucose and protein levels were increased in rats receiving cadmium through feed. All four key gluconeogenic enzymes were increased in both kidney and liver tissues of rats treated with cadmium. The present results indicate that cadmium may induce gluconeogenesis from non-carbohydrate sources.
...
PMID:Cadmium induced changes in gluconeogenic enzymes in rat kidney and liver. 721

Imperatorin, oxypeucedanine and chalepin are furanocoumarins isolated from Clausena anisata a medicinal plant common in West Africa. Only chalepin is found to have anticoagulant activity when administered to rats at a single dose. Aniline hydroxylase activity was appreciably depressed by each of the substances. Ethylmorphine demethylase, hepatic DNA, reduced glutathione and glucose-6-phosphatase were unaffected by these compounds when administered at a dose of 50 mg/kg for 3 days prior to sacrifice. Under similar conditions only chalepin treatment resulted in alpha-1-globulin increase and a decrease in beta-globulin content of the serum. Intraperitoneal treatment with chalepin (100 mg/kg) for 2 days resulted in the death of 4 rats out of 10 within a 48 h of treatment. Livers of dead rats showed generalized necrosis of hepatocytes. No deaths were recorded for imperatorin and oxypeucedanine. Rats surviving after 8 weeks showed no changes in hepatic enzyme activity, reduced glutathione and DNA concentrations. However, chalepin and imperatorin induced alterations in the serum protein pattern within this period. Liver lesions were observed in chalepin treated animals and were characterized by very mild necrosis of hepatocytes. No lesions were observed in the livers of rats treated with imperatorin and oxypeucedanine.
...
PMID:Structure-activity relationship in the toxicity of some naturally occurring coumarins-chalepin, imperatorin and oxypeucedanine. 726 93

Jejunoileal bypasses were performed in rats to determine the effect of improved absorption on the development of liver dysfunction occurring after this procedure. Several parameters of liver function were measured in rats 7 weeks after both the standard 85% small-bowel bypass and an 80% bypass in which an extra 5 cm of intact bowel was retained. Animals having undergone 80% bypass had a lesser degree of lowering of serum protein and triglyceride levels, hepatic cytochrome P-450 content, and hepatic glucose-6-phosphatase activity than did the animals undergoing 85% bypass. Abnormalities found in 85% bypass animals were only partially reproduced by reducing food intake in another group of 80% bypassed animals. These findings emphasize the importance of nutritional factors in the etiology of bypass-induced liver disease and militate against toxin production in the defunctionalized bowel as the sole cause of liver dysfunction following bypass.
...
PMID:Effect of improved absorption on development of jejunoileal bypass-induced liver dysfunction in rats. 739 17

The effect of two new chelating agents-Tiron (4,5-dihydroxy-1,3-benzene disulphonic acid disodium salt) and succinic acid--on the mobilization of beryllium was studied. Animals were exposed to beryllium nitrate (1 mg kg(-1) i.p.) daily for 21 days. Administration of beryllium nitrate showed a marked decrease in haemoglobin percentage, blood sugar, serum alkaline phosphatase and serum protein and a significant increase in the activity of transaminases. Tissue protein and glycogen contents and the activity of alkaline phosphatase, adenosine triphosphatase and succinic dehydrogenase showed significantly decreased values, but beryllium nitrate provoked a considerable increase in the activity of acid phosphatase and glucose-6-phosphatase in the vital and reproductive organs. Significant improvement in the haematological and biochemical parameters was observed with Tiron but no therapeutic effect was seen with succinic acid. Atomic absorption spectrophotometry (AAS) also showed a decreased level of beryllium concentration in the liver and kidney after Tiron therapy.
...
PMID:Influence of chelating agents on the toxicity and distribution of beryllium in rats. 980 33

In patients with glycogen storage disease type Ia (glucose-6-phosphatase deficiency), serum triglyceride concentrations are markedly raised, whereas phospholipids and cholesterol levels are only moderately elevated. In addition, both VLDL and LDL lipoprotein fractions are raised. Despite these abnormalities, endothelial vascular dysfunction and atherosclerosis seem to be rare in such patients. In view of the crucial role of apolipoprotein E (apoE) in lipid metabolism, we studied both apoE polymorphism (40 patients) and serum concentration (20 patients) in patients with glycogen storage disease type Ia. The distribution of each allele at the apoE locus was similar to that reported in the general population, whereas serum apoE concentrations were raised in our patients. Raised apoE levels in the serum could play an important role in counterbalancing the at-risk-for-atherosclerosis lipid profile of patients with glycogen storage disease type Ia. Moreover, E3 and E4 polymorphisms, predominant in our patients, have a high triglyceride binding capacity and are thus able to increase triglyceride clearance. However, the origin of raised concentrations of apoE is not completely clear though, bearing in mind previous reports regarding serum protein concentrations in such patients, increased hepatic synthesis is likely.
...
PMID:Apolipoprotein E polymorphism and serum concentrations in patients with glycogen storage disease type Ia. 1080 Oct 51

The efficacy of Tiron (4,5-dihydroxybenzene 1,3-disulfonic acid disodium salt) was examined in the treatment of beryllium-induced maternal and developmental toxicity in rats. Single administration of beryllium nitrate at a dose of 50 mg/kg (i.m.) on day 13 of gestation caused reductions in fetal and placental weights, the number of implantation sites and number of corpora lutea, as well as causing post-implantation loss, stunted growth, increase in the number of resorptions, and also a disturbed sex ratio. Maternal toxicity was demonstrated by reduction in body weight gain. Administration of beryllium also showed significant alteration in the hematological and biochemical indices of the mother as well as the fetus. Marked decreases were recorded in hemoglobin percentage, blood sugar levels, serum protein contents and serum alkaline phosphatase activity. By contrast, significant elevation was found in the activity of transaminases (aspartate aminotransferase and alanine aminotransferase). Tissue protein contents, glycogen contents, activities of alkaline phosphatase, adenosine triphosphatase and succinic dehydrogenase of kidney, lungs and uterus, and maternal and fetal liver all showed significantly decreased values after beryllium exposure, and remarkable elevation was observed in acid phosphatase, glucose-6-phosphatase and hepatic lipid peroxidation. These parameters were restored considerably with administration of 471 mg/kg i.m. Tiron from days 14 to 18 of gestation. Atomic absorption spectrophotometry also revealed a high concentration of beryllium in different organs of pregnant rats. Interestingly, a small amount of metal ion was also detected in the fetus and reduced accumulation of beryllium was noticed after Tiron treatment.
...
PMID:Protective effect of Tiron (4,5-dihydroxybenzene-1,3-disulfonic acid disodium salt) against beryllium-induced maternal and fetal toxicity in rats. 1218 11


1 2 Next >>

---